Deuruxolitinib phosphate - Generic Drug Details

What are the generic sources for deuruxolitinib phosphate and what is the scope of freedom to operate?

Deuruxolitinib phosphate is the generic ingredient in one branded drug marketed by Sun Pharm Inds Inc and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Deuruxolitinib phosphate has fifty-five patent family members in twenty-one countries.

One supplier is listed for this compound.

Summary for deuruxolitinib phosphate

International Patents:	55
US Patents:	6
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	2
Patent Applications:	26
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for deuruxolitinib phosphate
What excipients (inactive ingredients) are in deuruxolitinib phosphate?	deuruxolitinib phosphate excipients list
DailyMed Link:	deuruxolitinib phosphate at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for deuruxolitinib phosphate

Constraining patent/regulatory exclusivity:

NEW CHEMICAL ENTITY

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for deuruxolitinib phosphate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Concert Pharmaceuticals	Phase 1

See all deuruxolitinib phosphate clinical trials

Pharmacology for deuruxolitinib phosphate

Drug Class	Janus Kinase Inhibitor
Mechanism of Action	Bile Salt Export Pump Inhibitors Breast Cancer Resistance Protein Inhibitors Janus Kinase Inhibitors Multidrug and Toxin Extrusion Transporter 2 K Inhibitors Organic Anion Transporter 3 Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for deuruxolitinib phosphate

D11AH	Agents for dermatitis, excluding corticosteroids
D11A	OTHER DERMATOLOGICAL PREPARATIONS
D11	OTHER DERMATOLOGICAL PREPARATIONS
D	Dermatologicals

L01EJ	Janus-associated kinase (JAK) inhibitors
L01E	PROTEIN KINASE INHIBITORS
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

L04AF	Janus-associated kinase (JAK) inhibitors
L04A	IMMUNOSUPPRESSANTS
L04	IMMUNOSUPPRESSANTS
L	Antineoplastic and immunomodulating agents

US Patents and Regulatory Information for deuruxolitinib phosphate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sun Pharm Inds Inc	LEQSELVI	deuruxolitinib phosphate	TABLET;ORAL	217900-001	Jul 25, 2024		RX	Yes	Yes	12,285,432
Sun Pharm Inds Inc	LEQSELVI	deuruxolitinib phosphate	TABLET;ORAL	217900-001	Jul 25, 2024		RX	Yes	Yes	10,561,659
Sun Pharm Inds Inc	LEQSELVI	deuruxolitinib phosphate	TABLET;ORAL	217900-001	Jul 25, 2024		RX	Yes	Yes	12,247,034		Y	Y
Sun Pharm Inds Inc	LEQSELVI	deuruxolitinib phosphate	TABLET;ORAL	217900-001	Jul 25, 2024		RX	Yes	Yes	12,076,323
Sun Pharm Inds Inc	LEQSELVI	deuruxolitinib phosphate	TABLET;ORAL	217900-001	Jul 25, 2024		RX	Yes	Yes	12,364,699

International Patents for deuruxolitinib phosphate

Country	Patent Number	Title	Estimated Expiration
Japan	2022171838
European Patent Office	4654974
World Intellectual Property Organization (WIPO)	2023018904
Canada	3228505	TRAITEMENT DES TROUBLES DE LA CHUTE DES CHEVEUX PAR DES INHIBITEURS DE JAK DEUTERES (TREATMENT OF HAIR LOSS DISORDERS WITH DEUTERATED JAK INHIBITORS)
Finland	3452039

Market Dynamics and Financial Trajectory for Deuruxolitinib Phosphate

Last updated: February 20, 2026

What is the current market position of deuruxolitinib phosphate?

Deuruxolitinib phosphate is a selective JAK1/JAK2 inhibitor in clinical development targeting myeloproliferative disorders and certain inflammatory diseases. Its market potential hinges on regulatory approval, competitive landscape, and clinical efficacy data.

How does deuruxolitinib phosphate compare to existing treatments?

Existing JAK inhibitors like ruxolitinib and fedratinib dominate the myelofibrosis and polycythemia vera markets. Ruxolitinib, approved in 2011, generated global sales of $3.2 billion in 2022. Deuruxolitinib aims to improve upon efficacy and safety profiles, but has yet to secure market approval.

What are the regulatory and clinical development timelines?

Deuruxolitinib phosphate is in Phase 2 or Phase 3 trials as of 2023. No FDA or EMA approval has been granted. The typical pathway from Phase 3 to approval spans 1-2 years, contingent on trial outcomes. If positive data emerge in 2023-2024, commercial availability could occur by 2025 or 2026.

How does the competitive landscape influence market potential?

Major competitors include:

• Ruxolitinib (Incyte/Jannsen)
• Fedratinib (Janssen)
• Pacritinib (MAPS Pharma)

Deuruxolitinib’s market penetration depends on clinical advantages, pricing, and patent protections. Patent expiry for first movers may pressure pricing and market share.

What are the key market drivers and barriers?

Drivers:

• Unmet needs in treatment-resistant or intolerant patients.
• Demonstration of superior safety or efficacy.
• Expanded indication approvals.

Barriers:

• Clinical trial risks.
• Regulatory hurdles.
• Existing patent protections on competitors’ drugs.

What is the financial outlook for development-stage drugs like deuruxolitinib phosphate?

Development costs for JAK inhibitors are substantial, often exceeding $1 billion over a decade. The revenue potential upon approval could range from hundreds of millions to billions annually, assuming market uptake similar to early leaders.

The initial phase often involves licensing, subscriptions, and milestone payments. Commercial success depends on pricing strategies, reimbursement approvals, and market access capabilities.

How does patent and exclusivity status influence future revenue?

Patent protection typically lasts 10-12 years from filing, with extensions possible. As the drug approaches patent expiry, generic competition could erode market share unless new formulations or indications are secured.

What are the key risks impacting financial trajectory?

Major risks include failure to demonstrate sufficient clinical benefit, delays in regulatory approvals, or adverse safety findings. Competitive threats and patent cliffs may also impact long-term revenue streams.

Summary table: Financial and Market Indicators

Indicator	Data / Status
Clinical trial phase	Phase 2/3
Expected approval year	2025-2026 (if trials successful)
Estimated R&D investment	>$1 billion (over development cycle)
Market size estimate (2022)	Myeloproliferative disorder market approx. $4-5 billion
Leading competitor revenue (2022)	Ruxolitinib: $3.2 billion

Key Takeaways

• Deuruxolitinib phosphate is in late-stage clinical trials aiming to challenge existing JAK inhibitors.
• Market entry depends on positive trial outcomes and regulatory approval.
• Competition from established drugs like ruxolitinib significantly constrains upside.
• Development costs are high, while revenue potential depends on clinical success, pricing, and patent protections.
• Risks include trial failure, regulatory delays, and competitive pressures.

FAQs

1. When could deuruxolitinib phosphate reach the market?
Likely between 2025 and 2026, contingent on successful Phase 3 trials and regulatory review.

2. How does deuruxolitinib differ from ruxolitinib?
It aims to offer improved selectivity, safety, and efficacy, but clinical data are pending.

3. What are the primary indications targeted?
Myelofibrosis, polycythemia vera, and other inflammatory disorders.

4. What factors influence its commercial success?
Regulatory approval, clinical efficacy, safety profile, patent protection, and market competition.

5. How do patent expirations impact future revenues?
Patents lasting about 10-12 years from filing protect exclusivity; expiration can lead to generic entry and revenue declines unless new claims are pursued.

---

References

[1] Incyte Corporation. (2022). Ruxolitinib sales report.
[2] FDA. (2022). JAK inhibitor approval history.
[3] MarketResearch.com. (2023). Global myeloproliferative disorders market analysis.